Delineation ofMGMTHypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma
出版年份 2015 全文链接
标题
Delineation ofMGMTHypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma
作者
关键词
-
出版物
JNCI-Journal of the National Cancer Institute
Volume 108, Issue 5, Pages djv369
出版商
Oxford University Press (OUP)
发表日期
2015-11-29
DOI
10.1093/jnci/djv369
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors
- (2015) T. A. Hopkins et al. MOLECULAR CANCER RESEARCH
- MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide
- (2015) O. Erice et al. MOLECULAR CANCER THERAPEUTICS
- Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System
- (2015) K. E. Parrish et al. MOLECULAR CANCER THERAPEUTICS
- Mutant IDH1-Driven Cellular Transformation Increases RAD51-Mediated Homologous Recombination and Temozolomide Resistance
- (2014) Shigeo Ohba et al. CANCER RESEARCH
- Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program
- (2014) M. A. Smith et al. CLINICAL CANCER RESEARCH
- Discordant In Vitro and In Vivo Chemopotentiating Effects of the PARP Inhibitor Veliparib in Temozolomide-Sensitive versus -Resistant Glioblastoma Multiforme Xenografts
- (2014) S. K. Gupta et al. CLINICAL CANCER RESEARCH
- ABCB1, ABCG2, and PTEN Determine the Response of Glioblastoma to Temozolomide and ABT-888 Therapy
- (2014) F. Lin et al. CLINICAL CANCER RESEARCH
- Design and characterization of an economical192Ir hemi-brain small animal irradiator
- (2014) Michael P. Grams et al. INTERNATIONAL JOURNAL OF RADIATION BIOLOGY
- Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer
- (2014) Maha Hussain et al. INVESTIGATIONAL NEW DRUGS
- Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
- (2014) Roger Stupp et al. LANCET ONCOLOGY
- A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a Pediatric Brain Tumor Consortium report†
- (2014) Jack M. Su et al. NEURO-ONCOLOGY
- Bevacizumab for Newly Diagnosed Glioblastoma
- (2014) NEW ENGLAND JOURNAL OF MEDICINE
- Fundamental differences in promoter CpG island DNA hypermethylation between human cancer and genetically engineered mouse models of cancer
- (2013) Scott J Diede et al. Epigenetics
- Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
- (2013) Mark R. Gilbert et al. JOURNAL OF CLINICAL ONCOLOGY
- Patient-derived xenografts, the cancer stem cell paradigm and cancer pathobiology in the 21st century
- (2013) Samuel A Williams et al. LABORATORY INVESTIGATION
- Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation
- (2013) W. Wick et al. NEURO-ONCOLOGY
- Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma
- (2013) Lara Barazzuol et al. Radiation Oncology
- Abstract 5336: Macrophage migration inhibitory factor (MIF) plays roles in proliferation, survival and migration of Ewing tumor cells through the activation of several tyrosine kinases
- (2012) Hyung Gyoo Kang et al. CANCER RESEARCH
- Inhibition of Histone Deacetylation Potentiates the Evolution of Acquired Temozolomide Resistance Linked to MGMT Upregulation in Glioblastoma Xenografts
- (2012) G. J. Kitange et al. CLINICAL CANCER RESEARCH
- Characterization of a Large Panel of Patient-Derived Tumor Xenografts Representing the Clinical Heterogeneity of Human Colorectal Cancer
- (2012) S. Julien et al. CLINICAL CANCER RESEARCH
- Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial
- (2012) Annika Malmström et al. LANCET ONCOLOGY
- Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial
- (2012) Wolfgang Wick et al. LANCET ONCOLOGY
- Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: Activation of MET as one mechanism for drug resistance
- (2011) Rebekka Krumbach et al. EUROPEAN JOURNAL OF CANCER
- Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain
- (2011) Sagar Agarwal et al. EXPERT REVIEWS IN MOLECULAR MEDICINE
- Promoter Methylation in Head and Neck Squamous Cell Carcinoma Cell Lines Is Significantly Different than Methylation in Primary Tumors and Xenografts
- (2011) Patrick T. Hennessey et al. PLoS One
- A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatients") Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
- (2011) A. Bertotti et al. Cancer Discovery
- Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699
- (2010) R A Daniel et al. BRITISH JOURNAL OF CANCER
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
- (2010) Roel G.W. Verhaak et al. CANCER CELL
- ABT-888 Confers Broad In vivo Activity in Combination with Temozolomide in Diverse Tumors
- (2009) J. P. Palma et al. CLINICAL CANCER RESEARCH
- Radiosensitizing Effects of Temozolomide Observed in vivo only in a Subset of O6-Methylguanine-DNA Methyltransferase Methylated Glioblastoma Multiforme Xenografts
- (2009) Brett L. Carlson et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies
- (2009) Shivaani Kummar et al. JOURNAL OF CLINICAL ONCOLOGY
- Acquired Resistance to Combination Treatment with Temozolomide and ABT-888 Is Mediated by Both Base Excision Repair and Homologous Recombination DNA Repair Pathways
- (2009) X. Liu et al. MOLECULAR CANCER RESEARCH
- Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity
- (2009) T. M. Horton et al. MOLECULAR CANCER THERAPEUTICS
- Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines
- (2009) M. J. Clarke et al. MOLECULAR CANCER THERAPEUTICS
- MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
- (2009) Michael Weller et al. Nature Reviews Neurology
- Molecular Characterization of the Pediatric Preclinical Testing Panel
- (2008) G. Neale et al. CLINICAL CANCER RESEARCH
- Validation of Real-Time Methylation-Specific PCR to Determine O6-Methylguanine-DNA Methyltransferase Gene Promoter Methylation in Glioma
- (2008) Ilse Vlassenbroeck et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model
- (2008) Gaspar J. Kitange et al. JOURNAL OF NEURO-ONCOLOGY
- Potentiation of Temozolomide Cytotoxicity by Poly(ADP)Ribose Polymerase Inhibitor ABT-888 Requires a Conversion of Single-Stranded DNA Damages to Double-Stranded DNA Breaks
- (2008) X. Liu et al. MOLECULAR CANCER RESEARCH
- Genomic Changes and Gene Expression Profiles Reveal That Established Glioma Cell Lines Are Poorly Representative of Primary Human Gliomas
- (2008) A. Li et al. MOLECULAR CANCER RESEARCH
- Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts
- (2008) Gaspar J. Kitange et al. NEURO-ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started